Open AccessPost-progression survival is strongly linked to overall survival in refractory small-cell lung cancer patients who received amrubicin
Author(s) -
Hisao Imai,
Kyoichi Kaira,
Keita Mori,
Nodoka Watase,
Takeshi Hisada,
Masanobu Yamada,
Koichi Minato
Publication year - 2020
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_1170_16
Subject(s) - medicine , refractory (planetary science) , chemotherapy , oncology , lung cancer , progression free survival , biology , astrobiology
The benefits of second-line chemotherapy on the overall survival (OS) of small-cell lung cancer (SCLC) patients might be confounded by subsequent therapies. In this study, we aimed to determine the influence of progression-free survival (PFS) and postprogression survival (PPS) on OS after second-line chemotherapy in patients with refractory SCLC treated with amrubicin monotherapy.